10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Edwards Lifesciences's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 14.91%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Edwards Lifesciences's 10-Year ROIIC % or its related term are showing as below:
XSWX:EW's 10-Year ROIIC % is ranked better than 72.39% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 2.31
vs XSWX:EW: 14.91
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Edwards Lifesciences 10-Year ROIIC % Related Terms
Edwards Lifesciences 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EW vs DXCM, GEHC, BSX: 10-Year ROIIC % Comparison
For the Medical Devices subindustry, Edwards Lifesciences's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Edwards Lifesciences (XSWX:EW) has a 10-Year ROIIC % of 14.91 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Edwards Lifesciences and its competitors. According to the industry distribution chart, Edwards Lifesciences ranks #193 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 27.6%.
Is Edwards Lifesciences' 10-Year ROIIC % too high?
Edwards Lifesciences' current 10-Year ROIIC % is 14.91. The Medical Devices & Instruments industry median 10-Year ROIIC % is 2.31. Edwards Lifesciences' value of 14.91 is 545.5% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #193 out of 699 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' 10-Year ROIIC % compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #193 out of 699 companies for 10-Year ROIIC %. This puts Edwards Lifesciences in the upper half of its industry. The industry median 10-Year ROIIC % is 2.31. Edwards Lifesciences' value of 14.91 is 545.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.31, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current 10-Year ROIIC % of 14.91 is 545.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current 10-Year ROIIC % is 14.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current 10-Year ROIIC % of 14.91. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current 10-Year ROIIC % is 14.91 and 545.5% above the Medical Devices & Instruments industry median of 2.31. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current 10-Year ROIIC % is 14.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.
Key valuation signals for XSWX:EW:
10-Year ROIIC %: 14.91
GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
Industry Position: 545.5% above the Medical Devices & Instruments median (#193 of 699)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for XSWX:EW
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
